Philip Comp to Arthroplasty, Replacement, Knee
This is a "connection" page, showing publications Philip Comp has written about Arthroplasty, Replacement, Knee.
Connection Strength
0.424
-
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
Score: 0.184
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
Score: 0.075
-
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005 Oct; 87(10):2169-77.
Score: 0.063
-
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30; 349(18):1703-12.
Score: 0.055
-
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
Score: 0.047